Solid Biosciences Inc (SLDB): Koefisien rega marang pendapatan
Historically, the development of Solid Biosciences Inc. (SLDB) has been driven by strict FDA oversight and the struggle to mitigate vector toxicity. The price-to-sales ratio reflects the current market valuation, where the 11.90 mark characterizes this parameter. Prospects are based on grants amid negative FCF, while business resilience relies on the non-cyclical demand for gene therapy, which remains independent of macroeconomic trends.
Rincian metrik lan analitis perusahaan Solid Bio (SLDB)
- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi bursa:
- rincian nilai buku perusahaan:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Solid Biosciences Inc.|SLDB - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Solid Corp|SLDB - Gunggung utang perusahaan|Utang marang nilai buku Solid Bio|SLDB - Utang jangka dawa perusahaan|Utang jangka cendhak Solid Biosciences|Koefisien jangkoan perantara solidbio.com
- data bathi bisnis lan rasio investasi:
SLDB - Penghasilan resik|Penghasilan resik sing dikarepake Solid Biosciences Inc.|SLDB - Pangali P/E|Kapitalisasi marang proyeksi bathi Solid Biosciences Inc|SLDB - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Solid Bio|SLDB - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Solid Biosciences|SLDB - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan solidbio.com|SLDB - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Solid Biosciences Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:SLDB (solidbio.com)
High FDA regulatory risks and pressure from approved gene therapy counterparts make the valuation of Solid Biosciences Inc. (SLDB) extremely sensitive to market expectations. By analyzing the revenue multiple dynamics, an investor can observe the price-to-sales ratio, which allows them to filter out speculative noise and determine the fair value of this high-risk biotech asset.
Perusahaan pesaing
TEM - Rega marang dodolan|Rasio rega marang pendapatan Qiagen QGEN|Koefisien rega marang pendapatan Ionis Pharmaceuticals, Inc. (IONS)|Repligen Corp. - Multiplikator P/S|Avidity Corp (RNA) - Kapitalisasi marang pendapatan|CRSP: Multiplikator P/S|WGS - Koefisien rega marang pendapatan|RARE (Ultragenyx) - Multiplikator P/S|Rega marang dodolan Beam Therapeutics Inc BEAM|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Rasio kapitalisasi marang pendapatan|Multiplikator P/S TXG (10x Genomics, Inc.)|NTLA - Kapitalisasi marang pendapatan|Stoke Therapeutics, Inc. - Multiplikator P/S|Rega marang dodolan BioLife Solutions Inc|Wave Life Sciences Corp (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan SION|PRME: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TSHA|Koefisien rega marang pendapatan uniQure NV|Rasio rega marang pendapatan MeiraGTx PLC MGTX|RGNX: Rasio kapitalisasi marang pendapatan|Ocugen, Inc. - Multiplikator P/S|pacb.com (PACB) - Kapitalisasi marang pendapatan|BNTC (Benitec Biopharma) - Kapitalisasi marang pendapatan|DSGN - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Rocket Pharmaceuticals Inc|4D Molecular Corp (FDMT) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Lexeo Therapeutics (LXEO)|Rasio rega marang pendapatan KRRO (korrobio.com)|Multiplikator P/S EDIT (Editas Medicine)|SLN: Rasio kapitalisasi marang pendapatan|ProQR Therapeutics NV - Multiplikator P/S|CDXS: Rasio rega marang pendapatan|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan Metagenomi|Rasio kapitalisasi marang pendapatan DTIL (precisionbiosciences.com)|Multiplikator P/S GBIO|Multiplikator P/S Boundless Bio Inc (BOLD)|Rasio rega marang pendapatan Exicure XCUR|Koefisien rega marang pendapatan Imunon Inc (IMNN)|PHIO - Rasio rega marang pendapatan|Rega marang dodolan Mustang Bio, Inc.|transcodetherapeutics.com (RNAZ) - Rasio rega marang pendapatan|BNGO (Bionano Genomics) - Rasio rega marang pendapatan|APDN (Applied DNA Sciences) - Multiplikator P/S|bluebirdbio.com (BLUE) - Koefisien rega marang pendapatan|Multiplikator P/S IPA|Omega Therapeutics Inc - Rasio kapitalisasi marang pendapatan|Singular Genomics Systems Inc - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals - Multiplikator P/S|TBIO: Rasio rega marang pendapatan|TCON: Multiplikator P/S|UBX - Koefisien rega marang pendapatan
